Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Rhea-AI Summary

Scinai Immunotherapeutics (Nasdaq: SCNI) will attend BIO-Europe Spring 2026 in Lisbon March 23–25, showcasing its expanded CDMO platform and antibody-based immunology pipeline following the acquisition of Recipharm Israel and a strategic collaboration with Recipharm.

Highlights: integrated cGMP biologics site in Jerusalem, acquired cGMP small-molecule API site in Yavne, a client "graduation" model from early development to commercial supply, and a dermatology-focused antibody pipeline licensed from Max Planck, University Medical Center Göttingen, and PinCell.

Positive

• Acquisition of Recipharm Israel expands small-molecule API cGMP capacity
• Integrated CDMO model links early development through commercial manufacturing
• Strategic collaboration with Recipharm adds subcontracting capacity and technologies
• Antibody pipeline focused on autoimmune and dermatology indications with licensed assets

Negative

• None.

News Market Reaction – SCNI

-0.70%

1 alert

-0.70% News Effect

-2.6% Trough Tracked

-$18K Valuation Impact

$3M Market Cap

0.0x Rel. Volume

On the day this news was published, SCNI declined 0.70%, reflecting a mild negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. This price movement removed approximately $18K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

BIO-Europe Spring dates: March 23–25, 2026 Strategic pillars: 3 pillars Current price: $0.71 +1 more

4 metrics

BIO-Europe Spring dates March 23–25, 2026 BIO-Europe Spring 2026 conference in Lisbon

Strategic pillars 3 pillars Biologics site, small-molecule API site, Recipharm collaboration

Current price $0.71 Pre-news trading level vs 52-week high $6.18

52-week range $0.613–$6.18 SCNI 52-week low to high range before this news

Market Reality Check

Price: $0.7076 Vol: Volume 16,442 is below th...

low vol

$0.7076 Last Close

Volume Volume 16,442 is below the 20-day average of 52,130 (relative volume 0.32). low

Technical Shares at $0.71 are trading below the $1.38 200-day moving average and far under the $6.18 52-week high.

Peers on Argus

Biotech peers show mixed moves: GTBP (-0.23%), PBM (-2.31%), VRAX (-9.66%), whil...

1 Up 1 Down

Biotech peers show mixed moves: GTBP (-0.23%), PBM (-2.31%), VRAX (-9.66%), while LIPO (+6.25%) and SLRX (+18.98%) are up. Momentum scanner flags SPRC (+2.99%) and ELAB (-5.57%). This points to stock-specific rather than sector-wide drivers for SCNI.

Historical Context

5 past events · Latest: Mar 16 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Nasdaq compliance notice	Negative	+0.7%	Nasdaq notified SCNI of noncompliance with the $1.00 minimum bid rule.
Mar 2	Funding application & IP	Positive	-4.3%	Second amendment to PinCell option and revised €12M non-dilutive FENG funding bid.
Feb 25	Grant support expansion	Positive	+5.9%	Israel Innovation Authority allowed full use of NIS 5M robotic fill & finish grant.
Feb 17	Acquisition & collaboration	Positive	+2.9%	Completed Recipharm Israel acquisition and long-term collaboration expanding CDMO reach.
Jan 7	Industry roundtable role	Neutral	-3.2%	CEO scheduled to co-lead biopharma manufacturing roundtable at HealthIL Week 2026.

Pattern Detected

Recent news often leads to sizeable but mixed reactions, with positive strategic updates sometimes selling off and operational grants or CDMO expansion being better received.

Recent Company History

Over recent months, Scinai has focused on building an integrated CDMO and immunology platform. The company completed the Recipharm Israel acquisition and strategic collaboration, then secured expanded Israel Innovation Authority backing for a NIS 5 million robotic aseptic fill & finish program. It pursued non-dilutive funding for the PC111 program via a revised €12 million FENG application and faced a Nasdaq minimum $1.00 bid-price notice. Today’s BIO-Europe Spring 2026 participation showcases these expanded CDMO capabilities and the antibody-based immunology pipeline to potential partners and clients.

Market Pulse Summary

This announcement highlights Scinai’s expanded CDMO platform and antibody-based immunology pipeline ...

Analysis

This announcement highlights Scinai’s expanded CDMO platform and antibody-based immunology pipeline as it engages partners at BIO-Europe Spring 2026. It builds on recent steps such as the Recipharm Israel acquisition and Israel Innovation Authority support for robotic fill & finish. Investors may monitor how conference interactions translate into CDMO contracts, co-development deals, or licensing for the dermatology-focused pipeline, and how these developments affect a stock trading near its 52-week low and below the 200-day moving average.

Key Terms

cdmo, cGMP, api, immunotherapies, +2 more

6 terms

cdmo technical

"a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

cGMP regulatory

"a cGMP biologics development and manufacturing site in Jerusalem, a cGMP small-molecule API"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

api medical

"a cGMP small-molecule API development and manufacturing site in Yavne acquired from Recipharm"

An API, or Application Programming Interface, is a set of rules that allows different software programs to communicate and work together smoothly, much like a waiter translating your order into the kitchen and then bringing your meal back. For investors, APIs are important because they enable real-time access to financial data, trading systems, and other digital services, making it easier to make informed decisions quickly and efficiently.

immunotherapies medical

"a deep pipeline of antibody-based immunotherapies Scinai will present its growing pipeline"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

autoimmune medical

"antibody-based therapeutics targeting autoimmune and inflammatory diseases, with a primary focus"

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

tech transfer technical

"aligns quality and tech transfer standards to significantly reduce execution risk"

The transfer of technology is the process of handing over know‑how, manufacturing methods, regulatory data or intellectual property from one organization to another so a product or process can be made, scaled or sold. For investors it matters because smooth tech transfer determines how quickly a product reaches customers, how much it costs to scale, and whether a deal or license will produce reliable revenue — like giving a chef a tested recipe and clean kitchen so the dish comes out the same every time.

AI-generated analysis. Not financial advice.

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal.

This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufacturing capabilities.

The Scinai delegation will include:

• Amir Reichman, Chief Executive Officer, representing Scinai Immunotherapeutics' R&D activities
• Solomon Gahtan, Business Development & Alliance Management, Biologics
• Dr. Helen Domeshek, Business Development & Alliance Management, Small Molecules

Mr. Gahtan and Dr. Domeshek will represent Scinai Biopharma Services Ltd., the Company's CDMO subsidiary.

During the conference, the team will meet with pharmaceutical and biotechnology companies, investors, and prospective clients to advance both Scinai's innovative R&D pipeline and its integrated CDMO offering.

Expanding a Differentiated Integrated CDMO Platform from Early Development to Commercial Supply

Through Scinai Biopharma Services Ltd., the Company offers a differentiated, integrated CDMO platform supporting biotechnology and pharmaceutical companies from early development through commercialization.

Scinai's model is built on three strategic pillars: a cGMP biologics development and manufacturing site in Jerusalem, a cGMP small-molecule API development and manufacturing site in Yavne acquired from Recipharm, and a strategic commercial collaboration with Recipharm.

This structure positions Scinai as a unique partner bridging early-stage innovation with global commercial manufacturing. The Recipharm collaboration expands Scinai's capabilities through access to additional capacity and technologies via subcontracting, enables a seamless client "graduation" model from preclinical and clinical development to late-stage and commercial production, and aligns quality and tech transfer standards to significantly reduce execution risk and accelerate timelines.

At BIO-Europe Spring, Scinai will focus on engaging clients seeking flexible, high-quality development and manufacturing solutions with a clear, scalable path to commercialization.

Advancing a Deep Pipeline of Antibody-Based Immunotherapies

Scinai will present its growing pipeline of innovative antibody-based therapeutics targeting autoimmune and inflammatory diseases, with a primary focus on dermatology. The pipeline is based on assets licensed from the Max Planck Society, University Medical Center Göttingen, and PinCell S.r.l.

The Company is actively seeking strategic partnerships, co-development collaborations, and licensing opportunities with pharmaceutical and biotechnology companies to advance its pipeline.

"BIO-Europe Spring marks an important milestone for Scinai as we present our expanded capabilities following the Recipharm transaction," said Amir Reichman, Chief Executive Officer of Scinai. "We are uniquely positioned to partner with biotech and pharma companies across the full lifecycle of their products, from early-stage development through clinical and into commercial manufacturing, while also advancing a differentiated pipeline of immunology therapeutics. We look forward to engaging with partners who are seeking both innovation and execution."

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

For more information, please visit: www.scinai.com.

Company Contacts
Business Development | +972 8 930 2529 | bd@scinai.com
Investor Relations – Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the Company's participation in BIO-Europe Spring® 2026, its ability to advance its R&D pipeline, execute on business development opportunities, expand its CDMO capabilities, and realize the expected benefits of its acquisition of Recipharm Israel and the related commercial collaboration.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the risk that the recent acquisition of Recipharm Israel and strategic collaboration with Recipharm will not be as beneficial to the Company as anticipated, the Company's ability to successfully integrate acquired operations, attract and retain customers, advance its product candidates, secure partnerships, and general market and industry conditions. More detailed information regarding these and other risks and uncertainties is included in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-highlights-expanded-cdmo-platform-and-immunology-pipeline-at-bio-europe-spring-2026-302718695.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What did Scinai (SCNI) announce for BIO-Europe Spring 2026 participation?

Scinai will attend BIO-Europe Spring March 23–25, 2026 in Lisbon to present its expanded CDMO platform and immunology pipeline. According to the company, the appearance follows the Recipharm Israel acquisition and new strategic collaboration with Recipharm.

How does the Recipharm acquisition affect Scinai (SCNI) CDMO capabilities?

The acquisition adds a cGMP small-molecule API site in Yavne, expanding manufacturing capacity and capabilities. According to the company, this enables a seamless client "graduation" path from preclinical work to commercial supply.

What CDMO facilities does Scinai (SCNI) now operate after the transaction?

Scinai operates a cGMP biologics site in Jerusalem and a newly acquired cGMP small-molecule API site in Yavne. According to the company, these sites form an integrated platform supporting development through commercialization.

What pipeline programs will Scinai (SCNI) highlight at BIO-Europe Spring 2026?

Scinai will highlight antibody-based immunotherapies targeting autoimmune and inflammatory diseases, with a primary dermatology focus. According to the company, the pipeline includes assets licensed from Max Planck, University Medical Center Göttingen, and PinCell.

What partnership opportunities is Scinai (SCNI) seeking at BIO-Europe Spring 2026?

Scinai is seeking strategic partnerships, co-development deals, and licensing opportunities with biotech and pharma companies. According to the company, discussions will target both R&D collaborations and clients needing scalable CDMO services.